Injective and BDACS plan KRW1 settlement for tokenized assets

Injective and South Korean digital-asset custodian BDACS have signed a memorandum of understanding to make BDACS’s won-backed stablecoin KRW1 a settlement asset for tokenized assets on Injective. The companies say the arrangement would let markets price and settle in Korean won instead of routing through dollar stablecoins. Injective’s announcement describes the work as a collaboration to establish KRW1 for real-world asset and tokenization use cases; it does not give a launch date or describe a live integration.

KRW1 is issued by BDACS and, according to the company announcement, backed one-to-one by Korean won. Minting and redemption are planned for approved institutional partners and are subject to regulatory approval. That access condition matters to settlement: the proposed asset may be usable in onchain markets, but issuance and redemption are not described as open to every market participant.

How would KRW1 change settlement for tokenized assets?

KRW1 would provide a won-denominated settlement asset, so a tokenized asset market could settle in Korean won without converting through a US dollar stablecoin. The Block reported that the MOU positions KRW1 as the exclusive won-denominated settlement asset for real-world asset and tokenization activity on Injective. That scope is a stated partnership objective; the companies have not named a specific asset market or transaction flow that is live.

The difference is the unit used to price and settle a trade. If a Korean institution buys a tokenized asset priced in won, settlement in KRW1 could avoid the USD leg and its associated exchange-rate exposure. It would not remove the need to convert between won and other currencies when an asset or counterparty is denominated elsewhere. The partnership announcement does not specify how markets will source prices, process trades, or handle a KRW1 redemption request.

Injective says assets issued through its Injective Mint product have holder, jurisdiction and transfer controls at the protocol level. Those controls can restrict who holds or transfers an asset under an issuer’s requirements. The announcement does not say that KRW1 itself will use Injective Mint, or explain how those controls will interact with KRW1 settlement.

What has to happen before institutions can use it?

First, the parties must develop specific use cases with Korean financial institutions; then the relevant KRW1 issuance and redemption must be available to approved partners, subject to regulatory approval. BDACS chief executive Harry Ryoo said the companies would expand the collaboration as South Korea’s regulatory framework develops. Neither company has announced a deployment date, named participating institutions, or published a contract address or integration specification.

The won peg also depends on the reserve and redemption arrangements behind KRW1. BDACS describes the token as fully backed one-to-one, but the announcement does not detail reserve verification, redemption timing, or how settlement would be handled if an institution could not redeem. Those terms affect whether KRW1 can function as a reliable settlement asset beyond its stated denomination.

Injective says its network has processed more than $7.5 billion in real-world asset volume and issued more than $1 billion in tokenized assets. Those figures describe the network’s existing activity; they do not show how much of that volume could move to KRW1. For now, the MOU sets a direction for won-denominated markets, while the actual settlement design and institutional access remain to be specified.

References

• Injective’s announcement — injective.com
• reported that the MOU positions KRW1 as the exclusive won-denominated settlement asset — theblock.co